Treatment with tamoxifen

Malignant neoplasm of the endometrium - Treatment with tamoxifen Factor

Last reviewed for CCPS 30 April 1997.

Preliminary questions [14040]

16833 there is some evidence that treatment with tamoxifen may be a factor in the development of the condition under consideration.

1169 — the veteran is a woman.

14054

the veteran has been treated with tamoxifen at some time.

14056 the treatment with tamoxifen was given for an illness or injury which is identifiable.

14057 — the veteran has established the causal connection between the identified illness or injury for which the treatment with tamoxifen was given and VEA service for the clinical onset of malignant neoplasm of the endometrium.

14058 — the veteran has established the causal connection between the identified illness or injury for which the treatment with tamoxifen was given and operational service for the clinical onset of malignant neoplasm of the endometrium.

or

14059 — the veteran has established the causal connection between the identified illness or injury for which the treatment with tamoxifen was given and eligible service for the clinical onset of malignant neoplasm of the endometrium.

Clinical onset and operational service [14058]

14055

the veteran was treated with tamoxifen for the identified illness or injury before the clinical onset of malignant neoplasm of the endometrium.

14060 — the identified illness or injury for which the treatment with tamoxifen was given is causally related to operational service.

Clinical onset and eligible service [14059]

14107

the veteran was treated with tamoxifen for the identified illness or injury for a period of at least one year before the clinical onset of malignant neoplasm of the endometrium.

14061 — the identified illness or injury for which the treatment with tamoxifen was given is causally related to eligible service.